Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase I/II study in patients with various B-cell malignancies. Zanubrutinib was well tolerated and demonstrated activity in patients with relapsed/refractory mantle cell lymphoma.
[Blood Advances]
7992332
{7992332:N56VHKD3}
apa
50
1
163753
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
